CutisPharma announced today that it has appointed Neal Muni, MD, MSPH as President and member of the Board of Directors. Dr. Muni will assume responsibility for overseeing the company’s commercial operations and guiding development strategy for it’s product portfolio.

WILMINGTON, MA – July 15, 2014 – “We are pleased that Neal has joined our team to take our company to the next level of growth and continue our leading position as an innovator in pharmaceutical compounding,” said Dr. Indu Muni, Chief Executive Officer of CutisPharma. “Neal’s experience in the pharmaceutical industry, life science consulting, FDA and his background as a practicing physician bring a unique and highly effective skill set to develop our long-term strategic vision and build out the operational infrastructure to meet our goals.”

“I am thrilled to be joining CutisPharma at this exciting stage of the company’s history and leading its transformation into a fully-integrated industry leader in the pharmaceutical compounding market, said Neal Muni, President of CutisPharma. “We have a great opportunity to address the needs of patients by continuing to bring innovation to this niche sector of the industry and to significantly grow our business.”

Prior to joining CutisPharma, Dr. Muni served as the Executive Director of New Product Planning at Sunovion Pharmaceuticals, a US subsidiary of Dainippon Sumitomo Pharma, where he led the Corporate Strategy group’s commercial assessment of the company’s R&D portfolio and corporate M&A and licensing activities. Dr. Muni also currently maintains staff appointments with the Department of Medicine at Brigham and Women’s Hospital, where he practices as an internist with the Brigham Hospitalist Service, and Harvard Medical School, appointed as an Instructor of Medicine. Prior to joining Sunovion, Dr. Muni was an engagement manager in the strategic advisory practice of Leerink Swann, LLC, a Boston-based health-care boutique investment bank. Prior to that, Dr. Muni was a Medical Officer in the Division of Cardiovascular Devices at the FDA, serving as the lead medical reviewer for coronary drug eluting stent technologies. Dr. Muni completed his residency training in internal medicine at the Brigham and Women’s Hospital. He received his M.D. as well as Master of Science in Public Health, specializing in biostatistics, from the Tulane School of Medicine, and a B.A. in Business Economics and B.Sc. in Biochemistry from Brown University.

About CutisPharma

CutisPharma, Inc. based in Wilmington, MA, is a privately held, specialty pharmaceutical company focusing on the development and commercialization of value-added proprietary drug products and technologies in the prescription compounding sector of the pharmaceutical industry. Product line and development efforts are focused on providing optimized, more efficient alternatives for the preparation of the nearly 20 million currently compounded prescriptions, by offering FIRST® Unit-of-Use Prescription Compounding Kits. Use of these branded compounding kits will be beneficial to all triad participants, namely physicians, pharmacists, and patients. Four U.S. patents have been issued to the Company with additional patents pending, including “Composition and Method for Vancomycin Oral Liquid”.


James Nagle
V.P. Business Development
CutisPharma, Inc.
781-935-8141 x120

For more information please visit our website at